SCHEMBL14860135

SCHEMBL14860135

Cc1ccccc1CNC(=O)N(S)C(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 4/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ EPHX2 P34913 3/20 0.48
▸ CA2 P00918 1/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ LMNA P02545 2/20 0.45
▸ MAPT P10636 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ NR1H4 Q96RI1 2/20 0.44
▸ NPC1 O15118 2/20 0.43
▸ TAOK1 Q7L7X3 1/20 0.41
▸ TAOK3 Q9H2K8 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14859860 0.87 EPHX2 (0.49) HPGDEPHX2RAB9ALMNANR1H4
SCHEMBL14860316 0.80 EPHX2 (0.59) EPHX2RAB9ALMNAMAPTNR1H4
SCHEMBL14859138 0.79 NR1H4 (0.52) HPGDALDH1A1EPHX2RAB9ALMNA
SCHEMBL14859670 0.79 ALDH1A1 (0.54) HPGDALDH1A1CA2RAB9ALMNA
SCHEMBL14859532 0.78 NR1H4 (0.50) EPHX2RAB9ALMNANR1H4NPC1
SCHEMBL14859225 0.77 RAB9A (0.67) ALDH1A1EPHX2CA2RAB9ALMNA
SCHEMBL14860245 0.77 EPHX2 (0.54) ALDH1A1EPHX2RAB9ALMNAMAPT
SCHEMBL14860301 0.77 MEN1 (0.67) EPHX2RAB9ALMNANR1H4NPC1
SCHEMBL14859888 0.75 NR1H4 (0.51) ALDH1A1EPHX2RAB9ALMNAMAPT
SCHEMBL14860134 0.75 ALDH1A1 (0.59) HPGDALDH1A1EPHX2CA2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP claimed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US claimed
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP disclosed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT UGP2, TPMT, UPP1 HPGD 1311/4885ALDH1A1 1884/4885EPHX2 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback